Table 4.
Detected signals of NMS due to concomitant drug use.
| Combination of drugs (ROR of single drug) | |||||
|---|---|---|---|---|---|
| Risperidone (45.11) | Lithium carbonate (26.52) | 15 | 6.62 | 0.30 | 3.06 |
| Clomipramine hydrochloride (44.28) | 6 | 1.48 | 0.34 | 3.30 | |
| Aripiprazole (38.93) | Olanzapine (32.97) | 23 | 13.29 | 0.12 | 2.53 |
| Milnacipran hydrochloride (28.97) | 3 | 0.70 | − 0.50 | 2.16 | |
| Haloperidol (104.11) | Lithium carbonate (26.52) | 6 | 1.90 | 0.06 | 2.61 |
| Olanzapine (32.97) | Chlorpromazine hydrochloride, promethazine hydrochloride and phenobarbital (1)*,† (Suspension of sale) (34.61) | 6 | 1.96 | 0.03 | 2.53 |
| Sertraline hydrochloride (7.23) | 5 | 1.72 | − 0.22 | 2.12 | |
| Paroxetine hydrochloride hemihydrate (9.53) | Amantadine hydrochloride (25.23) | 3 | 0.70 | − 0.51 | 2.15 |
| Lithium carbonate (26.52) | Etizolam (11.38) | 3 | 0.50 | − 0.24 | 2.84 |
| Zotepine (39.73) | 10 | 1.75 | 1.19 | 5.86 | |
| Chlorpromazine hydrochloride, promethazine hydrochloride and phenobarbital (1)*,† (Suspension of sale) (34.61) | 5 | 1.69 | − 0.20 | 2.16 | |
| Donepezil hydrochloride (8.60) | Carbamazepine (2.52) | 3 | 0.65 | − 0.45 | 2.29 |
| Fluvoxamine maleate (14.02) | 3 | 0.70 | − 0.50 | 2.16 | |
| Carbamazepine (2.52) | Fluvoxamine maleate (14.02) | 3 | 0.69 | − 0.49 | 2.18 |
| Fluvoxamine maleate (14.02) | Clomipramine hydrochloride (44.28) | 7 | 1.55 | 0.61 | 3.98 |
| Etizolam (11.38) | Zotepine (39.73) | 4 | 0.61 | 0.28 | 3.69 |
NMS neuroleptic malignant syndrome, ROR reporting odds ratio.
*Sold only in Japan.
†The numbers are assigned because they were different product names due to differences in standards.